Biopharmaceutical News and Research

RSS

Retroviral replicating vector can extend lives of brain cancer patients

Doctors at UCLA, Cleveland Clinic, University of California San Diego School of Medicine and additional institutions have achieved a milestone in the development of a treatment for people with recurrent glioblastoma, the most common and aggressive form of brain cancer, by successfully demonstrating a modified virus that can extend the lives of patients with the disease.

2 Jun 2016

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion.

17 May 2016

American Thoracic Society and Sunovion release landmark survey of pulmonologists’ attitudes and practices with inhalation devices for COPD

The American Thoracic Society (ATS) and Sunovion Pharmaceuticals Inc. (Sunovion) today announced the results of a survey of pulmonologists and pulmonology fellows to determine physicians’ knowledge, attitudes, and practices related to chronic obstructive pulmonary disease (COPD) management, with particular attention to the use of hand-held small volume nebulizers. A small volume nebulizer is a device powered by air that aerosolizes medications for delivery to patients.

16 May 2016

Thermo Fisher Scientific reinforces ongoing commitment to make advanced technologies more accessible to customers

Thermo Fisher Scientific Inc., the world leader in serving science, today reinforced its ongoing commitment to help its customers accelerate innovation and enhance productivity.

12 May 2016

Researchers develop computer model to reveal how antibiotic-resistant microbes develop and spread

Researchers from the Scientific Research Institute of Physical-Chemical Medicine, MIPT, the company M&S Decisions and the research department of Yandex have built a computer model of the interaction between different bacteria, and between bacteria and the gut wall.

5 May 2016

Experimental treatment shrinks rare pediatric tumor by 90%

When a baby's life was threatened by a rare pediatric cancer that would not respond to surgery or chemotherapy, doctors at Nemours Children's Hospital rapidly, successfully shrank the tumor by 90 percent using an experimental treatment, according to a new study published online in Pediatric Blood and Cancer.

20 Apr 2016

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie, a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis.

15 Apr 2016

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12).

15 Apr 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

13 Apr 2016

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

AstraZeneca has presented positive data demonstrating the efficacy of the investigational antibiotic, ceftazidime-avibactam (CAZ-AVI), in treating patients with ceftazidime-resistant Gram-negative infections, which are increasingly resistant to most available antibiotics, often precipitating the need for clinicians to reach for agents previously reserved for last-line use.

12 Apr 2016

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph's Hospital and Medical Center.

7 Apr 2016

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

SCIEX, a global leader in life science analytical technologies, and QPS Holdings, LLC (QPS), a leading global full-service Contract Research Organization (CRO), today announced a collaboration to advance Hybrid LBA –LCMS, a workflow for routine biologics quantification. Under the agreement, QPS Holdings will deploy the SCIEX BioBA Solution, the first end-to-end and most complete solution for bioanalysis of biologics.

6 Apr 2016

Vanderbilt, Celgene collaborate to accelerate development of personalized therapies

Vanderbilt University Medical Center has entered into a strategic research agreement with Celgene Corporation, a biopharmaceutical company based in Summit, New Jersey.

5 Apr 2016

Beaumont urologists study use of enobosarm to treat women's SUI

Could a one-a-day pill be the answer for women with stress urinary incontinence - a condition resulting in leakage with coughing, sneezing and laughing?

30 Mar 2016

CCCBD offers promising new investigational therapy to treat childhood ALL

The Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles is one of the first sites in the world to offer a promising new investigational therapy to treat pediatric acute lymphoblastic leukemia (ALL).

30 Mar 2016

CRPS rank higher on pain scales than childbirth, cancer, amputation

Imagine pain in an arm or leg so intense that the sufferer would rather undergo an amputation than put up with it any longer. For those with complex regional pain syndrome (CRPS), this is not just a hypothetical nightmare—it is reality.

25 Mar 2016

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.

14 Mar 2016

BioLineRx announces year end 2015 financial results, provides operational update

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2015.

10 Mar 2016

Merck reports record results for 2015

Merck, a leading science and technology company, reported record results for 2015, emerging stronger from the transformation process that started in 2007. Net sales and EBITDA pre exceptionals were higher than ever before in Merck’s history of nearly 350 years.

From Merck 10 Mar 2016

Biopharmaceutical News and Research

Retroviral replicating vector can extend lives of brain cancer patients

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

American Thoracic Society and Sunovion release landmark survey of pulmonologists’ attitudes and practices with inhalation devices for COPD

Thermo Fisher Scientific reinforces ongoing commitment to make advanced technologies more accessible to customers

Researchers develop computer model to reveal how antibiotic-resistant microbes develop and spread

Experimental treatment shrinks rare pediatric tumor by 90%

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

Vanderbilt, Celgene collaborate to accelerate development of personalized therapies

Beaumont urologists study use of enobosarm to treat women's SUI

CCCBD offers promising new investigational therapy to treat childhood ALL

CRPS rank higher on pain scales than childbirth, cancer, amputation

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

BioLineRx announces year end 2015 financial results, provides operational update

Merck reports record results for 2015

Event guide: World ADC Asia eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News